John Sim, MD
Nephrology · Los Angeles, CANPI 1255490868
Payments from drug & device makers
What this record shows
Every reported general payment came from a single manufacturer, AstraZeneca. That places this record below the midpoint for nephrology clinicians in CA, where the typical reported total is $1,018.
Across 4 payments — averaging $129.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$517
Across 39 payments — averaging $34,701 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$833K
- Vertex$331K
- Mallinckrodt Enterprises LLC$81K
- AstraZeneca$77K
- Otsuka Pharmaceutical Co., Ltd.$20K
- Travere Therapeutics, Inc.$6K
- plus $5K from 1 others
What the payments were for
- Travel & lodging$23846%
- Food & beverage$27954%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 4 | $517 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ULTOMIRIS$486
How this compares
$517 in reported general payments places this provider in the 35th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 166 | $118,603 |
| EliquisApixaban | 12 | $26,120 |
| TradjentaLinagliptin | 22 | $21,401 |
| KerendiaFinerenone | 13 | $13,805 |
| Sevelamer Carbonate | 30 | $5,581 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $2,575 |
| Losartan Potassium | 99 | $1,377 |
| Furosemide | 78 | $1,357 |
| Spironolactone | 77 | $1,028 |
| Cinacalcet Hcl | 24 | $854 |
| Bisoprolol Fumarate | 40 | $801 |
| Glipizide | 59 | $760 |
| Carvedilol | 65 | $732 |
| Amiloride Hcl | 11 | $606 |
| Atorvastatin Calcium | 44 | $576 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Los Angeles
- Anjay RastogiLos Angeles$2.2M
- Suphamai BunnapradistLos Angeles$498K
- Mohammad KamgarLos Angeles$497K
- Victor CarabelloLos Angeles$363K
- Tariq ShahLos Angeles$351K
- Susanne NicholasLos Angeles$146K
- Arishia GhaffariLos Angeles$142K
- Allen NissensonLos Angeles$101K
- Niloofar NobakhtLos Angeles$97K
- Farid ArmanLos Angeles$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.